News Article

Shares in Spire Healthcare plunged over 20% on Monday, March 23, after private equity firms Bridgepoint and Triton formally abandoned their pursuit of the private hospital operator.

The dual withdrawal effectively dashes hopes of an imminent £1bn takeover that had sent the stock surging. Bridgepoint, which had reportedly been formulating a 230 pence per share offer, stated it was unable to gain sufficient confidence regarding a transaction structure that would satisfy all stakeholders. Triton similarly confirmed it had no intention of making a firm offer, abruptly narrowing the field of suitors ahead of a regulatory deadline.

Spire Healthcare confirmed that its strategic review, originally launched in September 2025, remains active. The company remains in an offer period and is continuing discussions with other unnamed parties regarding a potential sale. Management noted they are also evaluating alternative options, including value generation from the hospital property estate and adjustments to operational plans, to drive long-term sustainable shareholder value.

For investors and operators, the collapsed talks shift the focus back onto the underlying fundamentals of the company. While the operator recently reported a resilient performance for 2025, with group revenues rising to £1.58 billion and adjusted earnings reaching £268.6 million, the operating environment remains complex. The company is targeting flat earnings for 2026, citing significant cost headwinds from rising wages and material uncertainty surrounding National Health Service commissioning activity.

With a major buyout appearing off the table for now, the private healthcare provider will rely on its cost efficiency programmes and private patient growth strategy to navigate immediate sector pressures while the board searches for alternative paths to unlock value.